{"id":"anti-pd1","rwe":[{"pmid":"41806521","year":"2026","title":"Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.","journal":"European journal of cancer (Oxford, England : 1990)"},{"pmid":"41747313","year":"2026","title":"Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.","journal":"European journal of cancer (Oxford, England : 1990)"},{"pmid":"41740065","year":"2026","title":"Retrospective Study of Trametinib in Patients With Advanced NF1-Mutant Melanoma.","journal":"JCO precision oncology"},{"pmid":"41691529","year":"2026","title":"Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3.","journal":"Melanoma research"},{"pmid":"41375002","year":"2025","title":"MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.","journal":"Cancers"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06285097","NCT07421700","NCT04171141","NCT03915951","NCT04601402","NCT06447662","NCT07144280","NCT02890368","NCT04628780","NCT06580938","NCT06546553","NCT02573259","NCT04181788","NCT05926960","NCT04165317","NCT06448364","NCT04152018","NCT02133742","NCT06218069","NCT05061537","NCT06704724","NCT02179918","NCT04585815","NCT04458259","NCT05935748"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2017","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B164) — Advanced Solid Tumors"},{"date":"2022","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies) — Advanced Malignancies"},{"date":"2024","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer) — Non-muscle Invasive Bladder Cancer"}],"aiSummary":"Anti-PD1 is an immunotherapy that blocks the PD1 checkpoint inhibitor pathway to reinvigorate exhausted T cells and restore anti-tumor immunity. It is approved for various solid and hematologic malignancies where it has demonstrated improved survival outcomes. Key differentiator: enables the immune system to recognize and attack cancer cells that would otherwise evade detection.","brandName":"Anti-PD1","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Anti-PD1 PF-06801591","explanation":"Cancer cells have developed a clever trick to hide from your immune system. They display a protein called PD-L1 on their surface that binds to a receptor called PD1 on immune cells, sending a signal that essentially tells these immune cells to stand down and stop fighting. This is like cancer putting up a 'do not disturb' sign that your body's defenders respect.\n\nAnti-PD1 drugs work by blocking this interaction. They act as a shield that covers the PD1 receptor on immune cells, preventing cancer's PD-L1 signal from getting through. With this communication channel blocked, the immune cells no longer receive the 'stop fighting' message and instead resume their attack on cancer cells. It's essentially removing the muzzle from your immune system and unleashing it to do its job.\n\nOnce freed from this suppression, your T cells can recognize, multiply, and destroy cancer cells throughout the body. This approach has proven effective across multiple cancer types because it works with your body's natural defense mechanisms rather than introducing foreign substances, though it can sometimes lead to immune-related side effects as the newly activated immune system may also attack healthy tissue.","oneSentence":"Anti-PD1 PF-06801591","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"anti-pd1","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Gastrointestinal Tumors","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06285097","phase":"Phase 1","title":"A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumo","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":9,"indication":"Neoplasms","completionDate":"2025-01","primaryEndpoint":"This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with s"},{"nctId":"NCT07421700","phase":"Phase 1/2","title":"A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Can","status":"Not Yet Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":132,"indication":"Urothelial Cancer","completionDate":"2027-12","primaryEndpoint":"This study is being done to learn more about a new medicine called PF-08634404."},{"nctId":"NCT04171141","phase":"Phase 1","title":"Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metas","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":79,"indication":"Gastrointestinal Tumors","completionDate":"2023-11","primaryEndpoint":"A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors"},{"nctId":"NCT03915951","phase":"Phase 2","title":"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lun","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":98,"indication":"Non-small Cell Lung Cancer","completionDate":"2022-09","primaryEndpoint":"This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mut"},{"nctId":"NCT04601402","phase":"Phase 1","title":"GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors ","status":"Completed","sponsor":"Genome & Company","isPivotal":false,"enrollment":11,"indication":"Solid Tumor","completionDate":"2023-01","primaryEndpoint":"This is a phase I/Ib, first-in-human (FIH), open-label, dose escalation and dose expansion study to evaluate the safety and tolerability, biological and clinical activities of GEN-001 in patients with"},{"nctId":"NCT06447662","phase":"Phase 1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer The","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":330,"indication":"Carcinoma, Pancreatic Ductal","completionDate":"2027-09","primaryEndpoint":"The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies."},{"nctId":"NCT07144280","phase":"Phase 3","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Par","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":680,"indication":"Non-small Cell Carcinoma","completionDate":"2028-03","primaryEndpoint":"The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression gr"},{"nctId":"NCT02890368","phase":"Phase 1","title":"Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors an","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":56,"indication":"Solid Tumors","completionDate":"2020-03","primaryEndpoint":"This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fu"},{"nctId":"NCT04628780","phase":"Phase 1","title":"Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":37,"indication":"Non-small-cell Lung Cancer","completionDate":"2023-05","primaryEndpoint":"This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential cli"},{"nctId":"NCT06580938","phase":"Phase 1","title":"A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":4,"indication":"Non Small Cell Lung Cancer","completionDate":"2025-07","primaryEndpoint":"The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body."},{"nctId":"NCT06546553","phase":"Phase 1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of Pe","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Neoplasms","completionDate":"2025-10","primaryEndpoint":"The purpose of this study is to learn about the: * safety (the effect of the study medicine on the participant's body), * effects of the study medicine alone or in combination with sasanlimab - * the "},{"nctId":"NCT02573259","phase":"Phase 1","title":"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, ","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":147,"indication":"Part 1","completionDate":"2020-11","primaryEndpoint":"Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously trea"},{"nctId":"NCT04181788","phase":"Phase 1/2","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":155,"indication":"Advanced Malignancies","completionDate":"2022-03","primaryEndpoint":"This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with "},{"nctId":"NCT05926960","phase":"Phase 2","title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":38,"indication":"Melanoma","completionDate":"2026-02","primaryEndpoint":"The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment "},{"nctId":"NCT04165317","phase":"Phase 3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":1068,"indication":"Non-muscle Invasive Bladder Cancer","completionDate":"2024-12","primaryEndpoint":"The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer."},{"nctId":"NCT06448364","phase":"Phase 1","title":"A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone o","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":4,"indication":"Advanced or Metastatic Solid Tumors","completionDate":"2024-08","primaryEndpoint":"The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and t"},{"nctId":"NCT04152018","phase":"Phase 1","title":"Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":85,"indication":"Squamous Cell Carcinoma of the Head and Neck","completionDate":"2024-12","primaryEndpoint":"Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in "},{"nctId":"NCT02133742","phase":"Phase 1","title":"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination ","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":52,"indication":"Renal Cell Carcinoma","completionDate":"2017-03","primaryEndpoint":"Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon."},{"nctId":"NCT06218069","phase":"Phase 2/3","title":"Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor","status":"Not Yet Recruiting","sponsor":"Radboud University Medical Center","isPivotal":false,"enrollment":20,"indication":"NSCLC","completionDate":"2025-12","primaryEndpoint":"This study investigates whether a single subcutaneous administration of anti-PD-1 antibody can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with \\[89Zr\\]crefmirlimab berd"},{"nctId":"NCT05061537","phase":"Phase 1","title":"Study of PF-07263689 in Participants With Selected Advanced Solid Tumors","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":13,"indication":"Renal Cell Cancer","completionDate":"2022-10","primaryEndpoint":"This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and a"},{"nctId":"NCT06704724","phase":"Phase 1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer The","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":30,"indication":"Carcinoma, Pancreatic Ductal","completionDate":"2028-03","primaryEndpoint":"The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies."},{"nctId":"NCT02179918","phase":"Phase 1","title":"A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B164","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":23,"indication":"Advanced Solid Tumors","completionDate":"2017-02","primaryEndpoint":"This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of PF-05082566, a 4-1BB agonist mon"},{"nctId":"NCT04585815","phase":"Phase 1/2","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":34,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2023-05","primaryEndpoint":"Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study."},{"nctId":"NCT04458259","phase":"Phase 1","title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":88,"indication":"Neoplasm Metastasis","completionDate":"2024-11","primaryEndpoint":"A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors"},{"nctId":"NCT05935748","phase":"Phase 2","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carc","status":"Terminated","sponsor":"NiKang Therapeutics, Inc.","isPivotal":false,"enrollment":18,"indication":"ccRCC","completionDate":"2025-06","primaryEndpoint":"The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Dou"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL5315001"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":5,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}